Julie Rubinstein, Adaptive’s SVP of Business Development, will speak at Bloomberg’s State of Health Care 2014 Conference in New York City. She will participate on an expert panel entitled Innovation in Healthcare, which will feature the growth and promise of cancer immunotherapy.
Latest Press Releases
Adaptive continues to bolster its Board with leaders in healthcare and finance, positioning itself for the next level of growth
Adaptive announced today that Peter Neupert and Rob Rosen (pictured at left) will join its Board of Directors to strengthen its healthcare distribution system and software expertise and to add the financial experience necessary for commercialization.
Adaptive announced today a biomarker discovery agreement facilitated by the Johnson & Johnson Innovation Center in California. Under the agreement, Adaptive will use its patented immune profiling assay, immunoSEQTM, to enable an in-depth characterization of the immune response to diseases being studied and select immunology and oncology drugs being developed by Janssen Research & Development, LLC (Janssen). The exploration of immune response may identify patient populations more likely to respond to targeted therapies based on their immune status.
Adaptive announced today that Chad Robins, Founder and Chief Executive Officer, is scheduled to present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15th, 2014 at 2:00pm PST.
CBS News just published a story highlighting the promise of Adaptive’s QuanTILfy test that is being tested in many solid tumors for the prognosis, diagnosis, and monitoring of cancer patients. The article is based on a study published yesterday in Science Translational Medicine demonstrating that QuanTILfy may help predict survival in ovarian cancer patients.
Adaptive Biotechnologies and Collaborators Present 16 Studies Demonstrating Clinical Significance of ImmunoSequencing at 55th Annual Meeting of the American Society for Hematology
Adaptive and its collaborators will present data demonstrating how immunosequencing can inform survival in patients with blood cancers at the American Society of Hematology (ASH) meeting from December 7-10, 2013.
Adaptive Biotechnologies Publishes ‘Gold Standard’ Method for Sequencing Cells of the Adaptive Immune System
Adaptive announced today the publication of a method to significantly improve the accuracy of next-generation immune system profiling by creating a fully validated Synthetic Immune System (SISTM) to control for any possible bias caused by the amplification method used to characterize the enormous complexity of the adaptive immune system. The SIS method, developed and validated in Adaptive’s Seattle laboratories is described in the October 25th issue of Nature Communications, and demonstrates the Company’s fundamental commitment to data quality.
Adaptive Biotechnologies Receives Critical Intellectual Property for Next Generation Immunosequencing Field
Adaptive announced today that the Company has obtained a Notice of Allowance in U.S. Patent Application Serial No. 12/794,507, titled “Method of Measuring Adaptive Immunity,” exclusively licensed by Adaptive Biotechnologies from the Fred Hutchinson Cancer Research Center.
Adaptive Biotechnologies CEO Highlighting Companies Oncology Diagnostics Portfolio at Precision Medicine Conference in New York City
Adaptive CEO, Chad Robins, will be highlighting the companies’ pipeline of oncology diagnostics in a 30 minute presentation on October 10th at the Precision Medicine conference in NYC. Mr. Robins will focus on Adaptive’s state-of-the-art immune sequencing assays that are being used to discover and develop applications for prognosis, diagnosis, and monitoring over the life cycle of a cancer patient
Adaptive announced results from an ovarian cancer study, conducted in collaboration with Fred Hutchinson Cancer Research Center, highlighting the even distribution of immune fighter cells (T-cells) within the tumor. The study, published online in The Journal of Pathology ahead of the print publication, demonstrated the ability of Adaptive’s immunoSEQTM assay to assess the quantity and clonality of immune system cells within a tumor at a depth and specificity made possible by next-generation sequencing.